These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 17197824)

  • 1. Efavirenz-associated podocyte damage.
    Barbour TD; Furlong TJ; Finlayson RJ
    AIDS; 2007 Jan; 21(2):257-8. PubMed ID: 17197824
    [No Abstract]   [Full Text] [Related]  

  • 2. Hypersensitivity syndrome associated with efavirenz therapy.
    Bossi P; Colin D; Bricaire F; Caumes E
    Clin Infect Dis; 2000 Jan; 30(1):227-8. PubMed ID: 10619772
    [No Abstract]   [Full Text] [Related]  

  • 3. Efavirenz-associated severe hyperlipidemia.
    Bonnet F; Bonarek M; De Witte S; Beylot J; Morlat P
    Clin Infect Dis; 2002 Sep; 35(6):776-7. PubMed ID: 12203183
    [No Abstract]   [Full Text] [Related]  

  • 4. Recreational substance use and tolerance of efavirenz in HIV-1 infected patients.
    Faggian F; Lattuada E; Lanzafame M; Antolini D; Concia E; Vento S
    AIDS Care; 2005 Oct; 17(7):908-10. PubMed ID: 16120507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efavirenz and retinal toxicity.
    Lewis A; Mitchell S
    Eye (Lond); 2002 Jan; 16(1):107. PubMed ID: 11913879
    [No Abstract]   [Full Text] [Related]  

  • 6. A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection.
    Wolbach J; Capoccia K
    Nurse Pract; 1999 Jun; 24(6):81-2, 87-90, 92. PubMed ID: 10431297
    [No Abstract]   [Full Text] [Related]  

  • 7. Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis.
    Bickel M; Stephan C; Rottmann C; Carlebach A; Haberl A; Kurowski M; Staszewski S
    Scand J Infect Dis; 2005; 37(6-7):520-2. PubMed ID: 16012018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-related neutropaenia exacerbated by efavirenz.
    Healy BJ; Freedman AR
    HIV Med; 2006 Mar; 7(2):129-31. PubMed ID: 16420258
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA issues labeling changes for efavirenz.
    González-Lahoz J
    AIDS Rev; 2004; 6(3):181-2. PubMed ID: 15595435
    [No Abstract]   [Full Text] [Related]  

  • 10. Cortisol serum levels and their relationship to certain antiretroviral drugs.
    Collazos J; Ibarra S; Loureiro M
    Scand J Infect Dis; 2004; 36(6-7):480-2. PubMed ID: 15307572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropsychiatric effects of efavirenz: delayed onset.
    Dawson S; Woods C
    Int J STD AIDS; 2005 Nov; 16(11):769-70. PubMed ID: 16303077
    [No Abstract]   [Full Text] [Related]  

  • 12. Skin eruption 8 days after a single dose of efavirenz-containing combination therapy.
    Yazaki H; Kikuchi Y; Oka S
    Jpn J Infect Dis; 2001 Dec; 54(6):246-7. PubMed ID: 11862010
    [No Abstract]   [Full Text] [Related]  

  • 13. Safe substitution for efavirenz.
    AIDS Patient Care STDS; 2004 Jan; 18(1):58. PubMed ID: 15080097
    [No Abstract]   [Full Text] [Related]  

  • 14. Manic syndrome associated with efavirenz overdose.
    Blanch J; Corbella B; García F; Parellada E; Gatell JM
    Clin Infect Dis; 2001 Jul; 33(2):270-1. PubMed ID: 11418896
    [No Abstract]   [Full Text] [Related]  

  • 15. [Progress in HIV therapy. Effective and simple therapy with efavirenz].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():36-7. PubMed ID: 11373774
    [No Abstract]   [Full Text] [Related]  

  • 16. Severe vitamin D deficiency diagnosed after introduction of antiretroviral therapy including efavirenz in a patient living at latitude 59 degrees N.
    Gyllensten K; Josephson F; Lidman K; Sääf M
    AIDS; 2006 Sep; 20(14):1906-7. PubMed ID: 16954738
    [No Abstract]   [Full Text] [Related]  

  • 17. Efavirenz: innocent bystander or direct nephrotoxin?
    Wyatt CM; Rodriguez-Caprio G; Klotman PE
    AIDS; 2007 Jun; 21(10):1393. PubMed ID: 17545729
    [No Abstract]   [Full Text] [Related]  

  • 18. Recurrence of post-traumatic stress disorder and antiretrovirals.
    Damsa C; Bandelier C; Maris S; Lazignac C; Vidailhet P; Andreoli A; Bianchi-Demicheli F
    Scand J Infect Dis; 2005; 37(4):313-6. PubMed ID: 15880881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash.
    Manosuthi W; Thongyen S; Chumpathat N; Muangchana K; Sungkanuparph S
    HIV Med; 2006 Sep; 7(6):378-82. PubMed ID: 16903982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching from protease inhibitors to the non-nuke efavirenz.
    TreatmentUpdate; 2001; 12(12):3. PubMed ID: 11570089
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.